See Product Indications and Important Risk and Safety Information About DaTscan.
Please also read the Full Prescribing Information.
Visit the DaTscan brand website.
PRODUCT INICATONS AND USE: DaTscan is a radiopharmaceutical indicated for striatal dopamine transporter (DaT) visualization using single-photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected parkinsonian syndromes
(PS). In these patients, DaTscan may be used to help differentiate ET from tremor due to PS (idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy). DaTscan is an adjunct to other diagnostic evaluations.
CONTRAINDICATONS: DaTscan is contraindicated in patients with known hypersensitivity to the active subsctance, any of the excipients, or iodine.
DaTscan Provides Visual Clarity
Visualization of striatal DaT distribution can aid in the clinical diagnosis of PS, including1,2:
Important Risk and Safety Information About DaTscan: In clinical trials, reported adverse events consisted of headache, nausea, vertigo, dry mouth, or dizziness. These reactions were of mild to moderate severity. In postmarketing experience,
hypersensitivity reactions have been reported, generally consisting of skin erythema and pruritus. Injection-site pain also has been reported. To decrease thyroid accumulation of iodine 123, block the thyroid gland at least one hour before administration
of DaTscan; failure to do so may result in an increased long-term risk for thyroid neoplasia.
- Motor symptoms of parkinsonian syndromes are associated with striatal dopaminergic neuron loss1-3
- DaTscan binds presynaptically to striatal DaT and, when used with SPECT, may identify dopaminergic integrity4,5
- Differentiation between normal and abnormal scans is assessed by the extent (as indicated by shape) and intensity of the striatal signal following DaTscan administration and SPECT scanning2,6,7
1. Catafau AM, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004;19:1175-1182.
2. DaTscan [prescribing information]. Arlington Heights, IL: GE Healthcare; 2015.
3. Colloby SJ, Williams ED, Burn DJ, et al. Progression of dopaminergic degeneration in dementia with Lewy bodies and Parkinson's disease with and without dementia
assessed using 123I-FP-CIT SPECT. Eur J Nucl Med Mol Imaging. 2005;32:1176-1185.
4. Antonini A, Berto P, Lopatriello S, et al. Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy. Mov Disord. 2008;23:2202-2209.
5. Dodel RC, Höffken H, Möller JC, et al. Dopamine transporter imaging and SPECT in diagnostic work-up of Parkinson's disease: a decision-analytic approach. Mov Disord. 2003;18:S52-S62.
6. Winogrodzka A, Bergmans P, Booij J, et al. [123I]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease.
J Neurol Transm. 2001;108:1011-1019.
7. Asanuma K, Dhawan V, Carbon M, Eidelberg D. Assessment of disease progression in parkinsonism. J Neurol. 2004;251(suppl 7):VII/4-VII/8.